Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, C Ciardullo, ... Blood, The Journal of the American Society of Hematology 121 (8), 1403-1412, 2013 | 609 | 2013 |
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia D Rossi, S Rasi, G Fabbri, V Spina, M Fangazio, F Forconi, R Marasca, ... Blood, The Journal of the American Society of Hematology 119 (2), 521-529, 2012 | 563 | 2012 |
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness D Rossi, A Bruscaggin, V Spina, S Rasi, H Khiabanian, M Messina, ... Blood, The Journal of the American Society of Hematology 118 (26), 6904-6908, 2011 | 495 | 2011 |
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ... Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011 | 432 | 2011 |
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development D Rossi, V Trifonov, M Fangazio, A Bruscaggin, S Rasi, V Spina, S Monti, ... Journal of Experimental Medicine 209 (9), 1537-1551, 2012 | 428 | 2012 |
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia D Rossi, H Khiabanian, V Spina, C Ciardullo, A Bruscaggin, R Famà, ... Blood, The Journal of the American Society of Hematology 123 (14), 2139-2147, 2014 | 425 | 2014 |
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness D Rossi, M Cerri, C Deambrogi, E Sozzi, S Cresta, S Rasi, L De Paoli, ... Clinical cancer research 15 (3), 995-1004, 2009 | 419 | 2009 |
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia D Rossi, M Fangazio, S Rasi, T Vaisitti, S Monti, S Cresta, S Chiaretti, ... Blood, The Journal of the American Society of Hematology 119 (12), 2854-2862, 2012 | 398 | 2012 |
Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome D Rossi, M Cerri, D Capello, C Deambrogi, FM Rossi, A Zucchetto, ... British journal of haematology 142 (2), 202-215, 2008 | 306 | 2008 |
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma V Spina, A Bruscaggin, A Cuccaro, M Martini, M Di Trani, G Forestieri, ... Blood, The Journal of the American Society of Hematology 131 (22), 2413-2425, 2018 | 281 | 2018 |
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome D Rossi, V Spina, M Cerri, S Rasi, C Deambrogi, L De Paoli, L Laurenti, ... Clinical Cancer Research 15 (13), 4415-4422, 2009 | 255 | 2009 |
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma D Rossi, S Deaglio, D Dominguez-Sola, S Rasi, T Vaisitti, C Agostinelli, ... Blood, The Journal of the American Society of Hematology 118 (18), 4930-4934, 2011 | 236 | 2011 |
Diffuse large B-cell lymphoma genotyping on the liquid biopsy D Rossi, F Diop, E Spaccarotella, S Monti, M Zanni, S Rasi, C Deambrogi, ... Blood, The Journal of the American Society of Hematology 129 (14), 1947-1957, 2017 | 235 | 2017 |
Biology and treatment of Richter syndrome D Rossi, V Spina, G Gaidano Blood, The Journal of the American Society of Hematology 131 (25), 2761-2772, 2018 | 198 | 2018 |
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors D Rossi, E Sozzi, A Puma, L De Paoli, S Rasi, V Spina, A Gozzetti, ... British journal of haematology 146 (1), 64-75, 2009 | 188 | 2009 |
The genetics of nodal marginal zone lymphoma V Spina, H Khiabanian, M Messina, S Monti, L Cascione, A Bruscaggin, ... Blood, The Journal of the American Society of Hematology 128 (10), 1362-1373, 2016 | 169 | 2016 |
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness M Messina, I Del Giudice, H Khiabanian, D Rossi, S Chiaretti, S Rasi, ... Blood, The Journal of the American Society of Hematology 123 (15), 2378-2388, 2014 | 160 | 2014 |
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia D Rossi, V Spina, R Bomben, S Rasi, M Dal-Bo, A Bruscaggin, FM Rossi, ... Blood, The Journal of the American Society of Hematology 121 (24), 4902-4905, 2013 | 160 | 2013 |
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study R Bomben, M Dal Bo, D Capello, F Forconi, R Maffei, L Laurenti, D Rossi, ... British journal of haematology 144 (4), 492-506, 2009 | 154 | 2009 |
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study S Ferrero, D Rossi, A Rinaldi, A Bruscaggin, V Spina, CW Eskelund, ... Haematologica 105 (6), 1604, 2020 | 134 | 2020 |